Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Royalty Pharma PLC (RPRX : NSDQ)

• Company Description    Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. Number of Employees: 99

• Price / Volume Information    Yesterday's Closing Price: $38.64 Daily Weekly Monthly 20 Day Moving Average: 3,736,673 shares Shares Outstanding: 577.24 (millions) Market Capitalization: $22,304.48 (millions) Beta: 0.43 52 Week High: $41.24 52 Week Low: $25.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.30% -1.14% 12 Week 6.92% 5.19% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 110 East 59th Street - New York,NY 10022 USA ph: 212-883-0200 fax: - ir@royaltypharma.com http://www.royaltypharma.com

• General Corporate Information    Officers Pablo Legorreta - Chairman of the Board; Director & Chief Executive Terrance Coyne - Executive Vice President & Chief Financial Officer Bonnie Bassler - Director Errol De Souza - Director Catherine Engelbert - Director Peer Information Royalty Pharma PLC (CORR.) Royalty Pharma PLC (RSPI) Royalty Pharma PLC (CGXP) Royalty Pharma PLC (BGEN) Royalty Pharma PLC (GTBP) Royalty Pharma PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G7709Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/10/26 Share - Related Items Shares Outstanding: 577.24 Most Recent Split Date: (:1) Beta: 0.43 Market Capitalization: $22,304.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.28% Current Fiscal Quarter EPS Consensus Estimate: $1.51 Indicated Annual Dividend: $0.88 Current Fiscal Year EPS Consensus Estimate: $5.07 Payout Ratio: 0.19 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: -0.03 Estmated Long-Term EPS Growth Rate: 4.11% Last Dividend Paid: 11/14/2025 - $0.22 Next EPS Report Date: 02/10/26

• Fundamental Ratios P/E Current FY Estimate: 7.61 Trailing 12 Months: 8.55 PEG Ratio: 1.85 Price Ratios Price/Book: 2.33 Price/Cash Flow: 9.21 Price / Sales: 9.49 EPS Growth vs. Year Ago Period: 12.50% vs. Previous Quarter: 2.63% Sales Growth vs. Year Ago Period: 7.79% vs. Previous Quarter: 5.18% ROE 12/31/25 - - 09/30/25 - 26.36 06/30/25 - 25.54 ROA 12/31/25 - - 09/30/25 - 14.08 06/30/25 - 14.11 Current Ratio 12/31/25 - - 09/30/25 - 3.48 06/30/25 - 1.26 Quick Ratio 12/31/25 - - 09/30/25 - 3.48 06/30/25 - 1.26 Operating Margin 12/31/25 - - 09/30/25 - 110.08 06/30/25 - 110.45 Net Margin 12/31/25 - - 09/30/25 - 32.51 06/30/25 - 44.23 Pre-Tax Margin 12/31/25 - - 09/30/25 - 55.43 06/30/25 - 72.19 Book Value 12/31/25 - - 09/30/25 - 16.62 06/30/25 - 16.30 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.89 06/30/25 - 0.74 Debt-to-Capital 12/31/25 - - 09/30/25 - 47.10 06/30/25 - 42.43

Powered by Zacks Investment Research ©